Zydus Lifesciences Gets USFDA Nod for Asthma Medication
By Rediff Money Desk, New Delhi May 22, 2024 17:31
Zydus Lifesciences has received USFDA approval to market Theophylline extended-release tablets for asthma and COPD. The drug will be manufactured in Ahmedabad SEZ.

Photograph: Courtesy Zydus.
New Delhi, May 22 (PTI) Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat asthma.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Theophylline extended-release tablets (300 mg and 450 mg), the drug firm said in a statement.
Theophylline is used to treat asthma and chronic obstructive pulmonary disease (COPD).
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, the drugmaker said.
As per the IQVIA MAT data, Theophylline extended-release tablets (300 mg and 450 mg) had annual sales of USD 12.6 million in the US.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Theophylline extended-release tablets (300 mg and 450 mg), the drug firm said in a statement.
Theophylline is used to treat asthma and chronic obstructive pulmonary disease (COPD).
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, the drugmaker said.
As per the IQVIA MAT data, Theophylline extended-release tablets (300 mg and 450 mg) had annual sales of USD 12.6 million in the US.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.57 ( -9.52)
- 60265410
- Vodafone Idea L
- 8.27 (+ 0.73)
- 44071594
- YES Bank Ltd.
- 17.67 ( -0.56)
- 16081247
- G G Engineering
- 1.06 ( -4.50)
- 15019273
- Remedium Lifecare
- 3.97 (+ 4.75)
- 11827509
MORE NEWS
ABB India Profit Surges 54% to Rs 532 Cr in Q4
ABB India reported a 54% jump in net profit to Rs 532 crore in the December quarter,...

Magellanic Cloud Targets Rs 600 Crore Revenue...
Magellanic Cloud, a Hyderabad-based IT services provider, aims to achieve Rs 600 crore...
Choice Broking Acquires Arete Capital, AUM Hits...
Choice Broking has acquired wealth management firm Arete Capital Services, expanding...